On March 31, Zhejiang Shouxiangu Pharmaceutical Co.Ltd(603896) ( Zhejiang Shouxiangu Pharmaceutical Co.Ltd(603896) ) disclosed the annual report of 2021. During the reporting period, the company achieved an operating revenue of 767 million yuan, a year-on-year increase of 20.61%; The net profit was 201 million yuan, a year-on-year increase of 32.37%; The non net profit deducted was 199 million yuan, a year-on-year increase of 45.19%. The company plans to distribute a cash dividend of 4.05 yuan (including tax) to all shareholders for every 10 shares and increase 3 shares for every 10 shares.
Zhejiang Shouxiangu Pharmaceutical Co.Ltd(603896) is mainly engaged in the breeding, cultivation, processing and sales of rare Chinese medicinal materials such as Ganoderma lucidum, Dendrobium candidum and saffron. In May 2017, Zhejiang Shouxiangu Pharmaceutical Co.Ltd(603896) was successfully listed on the main board of Shanghai Stock Exchange, becoming the first share of Ganoderma lucidum and Dendrobium candidum industry in China Zhejiang Shouxiangu Pharmaceutical Co.Ltd(603896) traditional sales areas are concentrated in Zhejiang Province. From 2019 to 2021, the proportion of regional sales revenue in Zhejiang Province in the main business revenue was 63.92%, 64.28% and 63.45% respectively, and the proportion of Internet sales revenue was 20.22%, 23.12% and 24.40% respectively Zhejiang Shouxiangu Pharmaceutical Co.Ltd(603896) in the annual report, the company took the opportunity of landing in the capital market to gradually increase the marketing publicity, and the Internet sales revenue increased rapidly, which has become an important supplement to the traditional sales channels.
In the past year, the company established Jishi company to test the national market agent system. Running the Zhejiang Shouxiangu Pharmaceutical Co.Ltd(603896) small program such as Shou Xian Yun aims to create a new world of cloud sales, coordinate the integration of Shanghai and Jiangsu, and adjust the personnel market in Beijing, so as to seek a new situation in the foreign market.
Zhejiang Shouxiangu Pharmaceutical Co.Ltd(603896) said that in the future, the company will increase the investment attraction of spore powder tablet dealers in cities across the country, strive to expand markets outside the province and realize the multi regional development of the company.
Southwest Securities Co.Ltd(600369) research report shows that by the end of 2021, the company will vigorously explore channels outside the province. Through the mode of opening up new franchisees (Urban agents), the main development areas are Beijing, Shanghai, Guangzhou and Jiangsu. The market outside the province focuses on promoting high-end new dosage form spore powder tablets. The annual taking cost of tablets is 34 Shantui Construction Machinery Co.Ltd(000680) 00 yuan, and that of powder and granules is 1900039000 yuan respectively according to the taking situation. Dealers will give greater discounts. It is estimated that 30 urban agents will be added in 2022, and the market revenue outside the province will increase rapidly.
On the same day, Zhejiang Shouxiangu Pharmaceutical Co.Ltd(603896) disclosed the announcement of the plan for public issuance of convertible corporate bonds. The company plans to raise no more than 398 million yuan, which will be used for the construction of health food phase II of Zhejiang Shouxiangu Pharmaceutical Co.Ltd(603896) Health Industrial Park and the construction of R & D and testing center of Zhejiang Shouxiangu Pharmaceutical Co.Ltd(603896) health industrial park after deducting the issuance expenses.
